Identification of DGAT2 Inhibitors Using Mass Spectrometry

被引:15
作者
Song, Xuelei S. [1 ]
Zhang, Jiaping [2 ]
Chen, Xun [2 ]
Palyha, Oksana [3 ]
Chung, Christine [2 ]
Sonatore, Lisa M. [2 ]
Wilsie, Larissa [3 ]
Stout, Steven [2 ]
McLaren, David G. [2 ]
Taggart, Andrew [3 ]
Imbriglio, Jason E. [4 ]
Pinto, Shirly [3 ]
Garcia-Calvo, Margarita [2 ]
Addona, George H. [1 ]
机构
[1] Merck Res Labs, Dept Pharmacol, Boston, MA 02115 USA
[2] Merck Res Labs, Dept Pharmacol, Kenilworth, NJ 07033 USA
[3] Merck Res Labs, Atherosclerosis, Kenilworth, NJ 07033 USA
[4] Merck Res Labs, Discovery Chem, Kenilworth, NJ 07033 USA
关键词
LC/MS; DGAT2; triglycerides; DIACYLGLYCEROL ACYLTRANSFERASE; HEPATIC STEATOSIS; EXPRESSION; REDUCTION; INSULIN; ENZYMES; ASSAY;
D O I
10.1177/1087057115607463
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Mass spectrometry offers significant advantages over other detection technologies in the areas of hit finding, hit validation, and medicinal chemistry compound optimization. The foremost obvious advantage is the ability to directly measure enzymatic product formation. In addition, the inherent sensitivity of the liquid chromatography/mass spectrometry (LC/MS) approach allows the execution of enzymatic assays at substrate concentrations typically at or below substrate K-m. Another advantage of the LC/MS approach is the ability to assay impure enzyme systems that would otherwise be difficult to prosecute with traditional labeled methods. This approach was used to identify inhibitors of diacylglycerol O-acyltransferase-2 (DGAT2), a transmembrane enzyme involved in the triglyceride (TG) production pathway. The LC/MS approach was employed because of its increased assay window (compared with control membranes) of more than sevenfold compared with less than twofold with a conventional fluorogenic assay. The ability to generate thousands of dose-dependent IC50 data was made possible by the use of a staggered parallel LC/MS system with fast elution gradients. From the hit-deconvolution efforts, several structural scaffold series were identified that inhibit DGAT2 activity. Additional profiling of one chemotype in particular identified two promising reversible and selective compounds (compound 15 and compound 16) that effectively inhibit TG production in mouse primary hepatocytes.
引用
收藏
页码:117 / 126
页数:10
相关论文
共 21 条
  • [1] ENZYMES OF GLYCEROLIPID SYNTHESIS IN EUKARYOTES
    BELL, RM
    COLEMAN, RA
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 1980, 49 : 459 - 487
  • [2] DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis
    Buhman, KK
    Smith, SJ
    Stone, SJ
    Repa, JJ
    Wong, JS
    Knapp, FF
    Burri, BJ
    Hamilton, RL
    Abumrad, NA
    Farese, RV
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (28) : 25474 - 25479
  • [3] Targeting Acyl-CoA:Diacylglycerol Acyltransferase 1 (DGAT1) with Small Molecule Inhibitors for the Treatment of Metabolic Diseases
    Cao, Jingsong
    Zhou, Yingjiang
    Peng, Haibing
    Huang, Xinyi
    Stahler, Shannon
    Suri, Vipin
    Qadri, Ariful
    Gareski, Tiffany
    Jones, Juli
    Hahm, Seung
    Perreault, Mylene
    McKew, John
    Shi, Mengxiao
    Xu, Xin
    Tobin, James F.
    Gimeno, Ruth E.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (48) : 41838 - 41851
  • [4] Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis
    Cases, S
    Smith, SJ
    Zheng, YW
    Myers, HM
    Lear, SR
    Sande, E
    Novak, S
    Collins, C
    Welch, CB
    Lusis, AJ
    Erickson, SK
    Farese, RV
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (22) : 13018 - 13023
  • [5] Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members
    Cases, S
    Stone, SJ
    Zhou, P
    Yen, E
    Tow, B
    Lardizabal, KD
    Voelker, T
    Farese, RV
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (42) : 38870 - 38876
  • [6] CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans
    Chandler, CE
    Wilder, DE
    Pettini, JL
    Savoy, YE
    Petras, SF
    Chang, G
    Vincent, J
    Harwood, HJ
    [J]. JOURNAL OF LIPID RESEARCH, 2003, 44 (10) : 1887 - 1901
  • [7] Chen HC, 2002, J CLIN INVEST, V109, P1049, DOI 10.1172/JCI0214672
  • [8] Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance
    Choi, Cheol Soo
    Savage, David B.
    Kulkarni, Ameya
    Yu, Xing Xian
    Liu, Zhen-Xiang
    Morino, Katsutaro
    Kim, Sheene
    Distefano, Alberto
    Samuel, Varman T.
    Neschen, Susanne
    Zhang, Dongyan
    Wang, Amy
    Zhang, Xian-Man
    Kahn, Mario
    Cline, Gary W.
    Pandey, Sanjay K.
    Geisler, John G.
    Bhanot, Sanjay
    Monia, Brett P.
    Shulman, Gerald I.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (31) : 22678 - 22688
  • [9] A fluorescence-based thiol quantification assay for ultra-high-throughput screening for inhibitors of coenzyme A production
    Chung, Christine C.
    Ohwaki, Kenji
    Schneeweis, Jonathan E.
    Stec, Erica
    Varnerin, Jeffrey P.
    Goudreau, Paul N.
    Chang, Amy
    Cassaday, Jason
    Yang, Lihu
    Yamakawa, Takeru
    Kornienko, Oleg
    Hodder, Peter
    Inglese, James
    Ferrer, Marc
    Strulovici, Berta
    Kusunoki, Jun
    Tota, Michael R.
    Takagi, Toshimitsu
    [J]. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2008, 6 (03) : 361 - 374
  • [10] LOCALIZATION AND PARTIAL CHARACTERIZATION OF ACYLTRANSFERASES PRESENT DURING RAPID MEMBRANE FORMATION IN DROSOPHILA-MELANOGASTER EMBRYO
    HECKMAN, CA
    FRIEDMAN, SJ
    SKEHAN, PJ
    BARRNETT, RJ
    [J]. DEVELOPMENTAL BIOLOGY, 1977, 55 (01) : 9 - 32